$BCLI

BRAINSTORM CELL THERAPEUTICS INC.

BrainStorm Cell Therapeutics is a biotechnology company developing autologous cell therapies for neurodegenerative diseases, including ALS, progressive multiple sclerosis and Alzheimer’s disease. Its NurOwn® platform uses a patient’s own bone marrow-derived mesenchymal stem cells, processed to secrete neurotrophic factors, and is administered into the cerebrospinal fluid by lumbar puncture. The company’s clinical programs include NurOwn® trials in ALS and progressive multiple sclerosis, and development for Alzheimer’s disease. It has completed Phase 3 ALS and Phase 2 progressive multiple sclerosis trials and has an FDA-agreed design for a planned Phase 3b ALS trial. BrainStorm makes money through development and commercialization of its cell therapy technology; its Israeli subsidiary holds exclusive rights to commercialize NurOwn® under a licensing agreement with Ramot, Tel Aviv University’s technology transfer company. BrainStorm has 20 employees in the United States and Israel, with an R&D center in Petach Tikva, Israel, and its headquarters in New York, NY.

0
4
0

No SEC Form 4 filings for $BCLI in the last 30 days.

See all $BCLI insider activity →
Med

BRAINSTORM CELL THERAPEUTICS INC. (BCLI): Notice of Pendency and Proposed Settlement of Stockholder

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK IN RE BRAINSTORM CELL Lead Case No. 1:24-cv-01095-DEH THERAPEUTICS, INC. DERIVATIVE LITIGATION EXHIBIT C NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER DERIVATIVE MATTERS TO: ALL RECORD HOLDERS AND

BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics (BCLI) reported Q3 2026 financial results, with a net loss of $1.7M, down from $2.1M in Q3 2025. The company is preparing for a Phase 3b study of NurOwn® for ALS, supported by an FDA-agreed protocol. They appointed Peter J. Pitts as Executive Chairman to lead regulatory and strategic initiatives. Cash reserves increased to $0.35M from $0.24M year-over-year.

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics (OTCQB: BCLI) reported Q2 2026 results for the quarter ended June 30, 2026. It said it is preparing to start the Phase 3b ENDURANCE study of NurOwn in ALS under an FDA-agreed Special Protocol Assessment, planning about 200 patients. Cash was about $0.2M vs $1.03M a year earlier, with Q2 net loss about $3.9M. The company appointed Peter J. Pitts as Executive Chairman and raised about $400k in private placements.

BCLI sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning BCLI (BRAINSTORM CELL THERAPEUTICS INC.). Coverage has been balanced: 0 bullish, 4 neutral, and 0 bearish.

Recent BCLI coverage spans financial news, earnings and corporate actions.

What's driving BCLI

  • Settlement terms and governance reforms may reduce litigation overhang, but the underlying allegations (FDA issues, misstatements) can still weigh on sentiment until the court approves.

    SEC EDGAR 8-K · Nov 20, 2026

  • The update reinforces near-term clinical/regulatory execution while highlighting continued cash burn and balance-sheet strain.

    prnewswire.com · Nov 16, 2026

  • Near-term trading focus is funding runway and execution risk for the FDA SPA Phase 3b ENDURANCE launch, plus leadership change.

    prnewswire.com · Aug 14, 2026

  • Near-term trading focus is cash burn and financing risk, offset by a regulatory milestone path for the Phase 3b ENDURANCE trial.

    SEC EDGAR 8-K · Aug 14, 2026

  • The filing discloses CEO equity compensation terms, which can affect near-term sentiment but is not a fundamental operating update.

    SEC EDGAR 8-K · Jul 30, 2026

AlphAI scores every news story that mentions BCLI with an AI model for sentiment and relevance, and aggregates insider trades from BRAINSTORM CELL THERAPEUTICS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $BCLI

Score

BRAINSTORM CELL THERAPEUTICS INC. (BCLI): Notice of Pendency and Proposed Settlement of Stockholder

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK IN RE BRAINSTORM CELL Lead Case No. 1:24-cv-01095-DEH THERAPEUTICS, INC. DERIVATIVE LITIGATION EXHIBIT C NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER DERIVATIVE MATTERS TO: ALL RECORD HOLDERS AND

$BCLIMedEarnings

BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics (BCLI) reported Q3 2026 financial results, with a net loss of $1.7M, down from $2.1M in Q3 2025. The company is preparing for a Phase 3b study of NurOwn® for ALS, supported by an FDA-agreed protocol. They appointed Peter J. Pitts as Executive Chairman to lead regulatory and strategic initiatives. Cash reserves increased to $0.35M from $0.24M year-over-year.

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics (OTCQB: BCLI) reported Q2 2026 results for the quarter ended June 30, 2026. It said it is preparing to start the Phase 3b ENDURANCE study of NurOwn in ALS under an FDA-agreed Special Protocol Assessment, planning about 200 patients. Cash was about $0.2M vs $1.03M a year earlier, with Q2 net loss about $3.9M. The company appointed Peter J. Pitts as Executive Chairman and raised about $400k in private placements.

$BCLIMedEarnings

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK, Aug 14, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerativ

$BCLILowExec change· appointed

BRAINSTORM CELL THERAPEUTICS INC. (BCLI): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman Professor Jacob Frenkel Transitions to Senior Advisor Peter J. Pitts to lead NurOwn® into Phase 3b trial; advancing under the first Special Protocol Assessment ever granted for

Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Brainstorm Cell Therapeutics Inc. (OTC: BCLI); Flywire Corporation (NASDAQ: FLYW); and Ibotta, Inc. (NYSE: IBTA): Grabar Law Office is Investigating Claims on Your Behalf - Brainstorm Cell (OTC:BCLI), Alto Neuroscience (NYSE:ANRO)

PHILADELPHIA, Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- Grabar Law Office is investigating claims on behalf of shareholders of Alto Neuroscience, Inc. ANRO. The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

Related tickers